Is Carie Boyd Pharmaceuticals legit?

Carie Boyd Pharmaceuticals is a Both compounding pharmacy based in Irving, TX. It operates under state board of pharmacy licensure. Note: our records show 2 documented regulatory action(s) — see the Regulatory Actions section below.

Where is Carie Boyd Pharmaceuticals located?

Carie Boyd Pharmaceuticals is headquartered in Irving, TX. The pharmacy is licensed to ship to 0 US states.

What does Carie Boyd Pharmaceuticals produce?

Carie Boyd Pharmaceuticals produces compounded semaglutide in addition to other compounded preparations. As a Both pharmacy, it operates both a patient-specific 503A division and an FDA-registered 503B outsourcing facility.

What is the difference between 503A and 503B?

503A pharmacies prepare compounded medications for individual patients in response to specific prescriptions and are regulated primarily by state boards of pharmacy under USP sterile compounding standards. 503B outsourcing facilities register directly with the FDA, follow current Good Manufacturing Practices (cGMP), and can produce compounded medications in larger batches without patient-specific prescriptions. 503B facilities are subject to FDA inspection.

Compounding Pharmacy · Irving, TX · Both

Carie Boyd Pharmaceuticals Review

Carie Boyd Pharmaceuticals is a Texas-based compounding pharmacy operated by Right Value Drug Stores, LLC. The company runs an FDA-registered 503B outsourcing facility at 8400 Esters Blvd, Suite 190, Irving, TX 75063 (registered with FDA as an outsourcing facility on July 3, 2019), plus a 503A patient-specific compounding pharmacy doing business as Carie Boyd's Prescription Shop in Denton, TX (also referenced at 122 Grapevine Hwy, Hurst, TX per NPPES NPI 1205253085, Texas pharmacy license 165). The 503A pharmacy roots trace to a community pharmacy founded in 1965 in the Dallas-Fort Worth area. For GLP-1 weight management, Carie Boyd markets a sublingual semaglutide suspension compounded exclusively with commercially available Rybelsus tablets in a SubMagna sublingual base (starting dose 1 mg/day, titrated to ~1.5 mg/day); no public marketing was found for compounded tirzepatide. The company received an FDA Warning Letter on December 17, 2024 (reference 694687) citing 503B compliance and labeling deficiencies, and a prior Warning Letter on September 20, 2021 (reference 610751) following a 2019 inspection. Both warning letters reduce confidence in this pharmacy for telehealth-provider sourcing relative to peers without active FDA enforcement on file.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

BothFDA-registered 503B outsourcing facility

Location: Irving, TX

Website: www.carieboyd.com

States licensed: 0

5.0

Weight Loss Rankings Score

out of 10

About this pharmacy

Certifications & Compliance

All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards^[4], with finished preparations evaluated against USP <71> sterility testing^[5] and USP <85> bacterial endotoxin testing^[6] as appropriate for the product type.

FDA-registered 503B outsourcing facility

Additional certification disclosed by the pharmacy.

Drugs Produced

Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list^[7].

Yes

Semaglutide

Compounded semaglutide produced

—

Tirzepatide

Not produced

States Licensed (0)

Regulatory Actions

2024-12-17

2021-09-20

Weight Loss Rankings Score Breakdown

Accreditation & Compliance6/10

Regulatory Standing5/10

State Coverage0/10

GLP-1 Production5/10

Track Record5/10

Scores are independently researched. See our methodology for details.

Medium confidence · Last verified 2026-05-28 via Eli Marsden · How we verify provider data

Frequently Asked Questions

Glossary references

Key terms in this article, linked to their canonical definitions.

Semaglutide · Drugs and brands
Tirzepatide · Drugs and brands
Compounded GLP-1 · Pharmacy and drug forms
503A pharmacy · Pharmacy and drug forms
503B outsourcing facility · Pharmacy and drug forms
PCAB accreditation · Pharmacy and drug forms
Off-label use · Insurance and regulatory
FDA Drug Shortage List · Insurance and regulatory

See Top Semaglutide Providers All Pharmacies

Sources & methodology — as of May 2026

1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.